Based on observations in irradiated populations, the health risks of low-level exposure to ionizing radiation have been assumed to be related primarily to cancer. At high radiation doses a variety of other well-established effects are observed, in particular, damage to the structures of the heart and to the coronary, carotid, and other large arteries. This damage occurs both in patients receiving radiotherapy and in experimental animals ([@r2]). There are plausible, if not completely understood, mechanisms by which high doses of radiation affect the blood circulatory system ([@r37]). Recent analyses of the Japanese atomic-bomb survivors have suggested that excess mortality from noncancer disease was comparable to that from cancer ([@r33]; [@r34]).

An association between lower doses (\< 0.5 Gy) and late circulatory disease has only recently been suspected and remains controversial. Recent reviews have presented evidence suggesting an excess radiation-induced risk at occupational and environmental dose levels \[Advisory Group on Ionising Radiation (AGIR) 2010; [@r26]\]. In particular, a review by the Health Protection Agency's AGIR in the United Kingdom estimated substantial excess risks for ischemic heart disease (IHD) and stroke, but concluded that a significantly elevated risk was detectable only for exposures above about 0.5 Gy (AGIR 2010). The AGIR report also reviewed biological data suggesting that many inflammatory end points potentially relevant to circulatory disease may be differentially regulated below and above about 0.5 Gy (AGIR 2010), emphasizing the importance of assessing risks associated with exposures of \< 0.5 Gy.

Here, we test the hypothesis of a causal association between low-level radiation exposure and circulatory disease in a general unselected population. We estimate population circulatory disease mortality risks from low doses of radiation by extending recent meta-analyses (AGIR 2010; [@r25], [@r27], [@r26]) of Japanese atomic-bomb survivors and occupationally exposed groups, taking heterogeneity among studies into account. The results of the meta-analysis are used to estimate the potential radiation-related mortality risks of circulatory disease in various populations and to compare them with the risks of cancer.

Data and Methods
================

*Data and meta-analysis.* Searches of the PubMed (U.S. National Library of Medicine, Washington, DC, USA) and ISI Thomson (Web of Knowledge, New York, New York, USA) databases were conducted on 14 May 2011 and 17 August 2011, respectively, using the terms "radiation" AND "heart" AND "disease," OR "radiation" AND "stroke," OR "radiation" AND "circulatory" AND "disease." The ISI Thomson database search was restricted to human data. Only peer-reviewed papers from 1990 onward that had reliable ascertainment of circulatory disease morbidity or mortality were considered; abstracts and letters were not included. There was no restriction on the type of study design (e.g., cohort, case--control, case--base). Abstracts and papers were manually reviewed by M.P.L. and W.Z. A total of 4,971, 1,180, and 526 articles were published in PubMed in these categories since 1990; the ISI Thomson search (which was conducted using all three groups of search words combined) returned a total of 1,480 articles. Although there was no restriction to publication in English, based on assessment of the titles and abstracts the only studies meeting our criteria were published in that language.

Studies were excluded if there was no analysis of circulatory disease in relation to individual exposures or if there was not a reliable (e.g., film-badge or area-monitoring based) estimate of whole-body dose. All of the studies included in the analysis expressed radiation dose in sieverts (Sv), which should be very similar to unweighted absorbed doses in gray (Gy) \[International Commission on Radiological Protection (ICRP) 2007\]. Exposures had to involve moderate- or low-dose (cumulative mean \< 0.5 Sv) whole-body exposure, or exposures at a low dose rate (i.e., \< 10 mSv/day) and so included studies of environmental exposures, occupational exposures, or exposures experienced by Japanese atomic-bomb survivors. The reason for emphasizing uniform whole-body exposure is that the target tissue for radiation-associated circulatory disease is not known, thus whole-body dose \[which will be approximately the same as dose to any tissue (ICRP 2007)\] is the most reliable metric with which to compare studies. However, we also included two occupationally exposed groups with some degree of nonuniformity in exposure (e.g., in relation to liver, lung, and bone dose), although with uniform dose to the circulatory system ([@r5], [@r6]; [@r18]). The requirement for uniform whole-body dose and analysis of circulatory disease in relation to individual dose resulted in the exclusion of a number of otherwise eligible studies, for example, the Massachusetts tuberculosis fluoroscopy cohort ([@r10]).

We excluded studies of any cohort in which the additional follow-up amounted to ≤ 1 year with respect to the larger analysis in which it is included. Therefore, we excluded U.S. and Canadian nuclear worker studies ([@r15]; [@r58]) that had no more follow-up (to 31 December 1997 and to 31 December 1994, respectively) than the International Agency for Research on Cancer (IARC) 15-country study ([@r50]) that subsumed them. We also excluded the Canadian National Dose Registry study ([@r59]) that overlaps with the Canadian nuclear worker data ([@r58]) and has a somewhat lower quality of linkage to employment records and verification of dosimetry ([@r14]) as well as a study by [@r4] subsumed within the latest National Registry for Radiation Workers analysis cohort ([@r31]) and with earlier final follow-up (end 1997 vs. end 2001). Recent analyses of circulatory and related end points in the Japanese atomic-bomb survivor cohort that were published after our literature search were also not included ([@r1]; [@r33]; [@r45], [@r44]); the mortality study of [@r33] had identical follow-up (1950--2003) to an earlier paper by [@r39] that was included in our analysis.

Having derived the primary study populations, we further selected studies so as to be more or less disjoint. We therefore did not include the study of [@r35] because it is largely subsumed in the IARC 15-country study of [@r50], with minimal extra years of follow-up \[to 31 December 1990 for [@r35] vs. 31 December 1984 for [@r50]\]. Likewise, we did not include the study of [@r29] because the British Nuclear Fuels Limited worker cohort is largely subsumed within the study of [@r31] and has only 4 more years of follow-up \[to 31 December 2005 vs. 31 December 2001 for [@r31]\]. However, we tested for the effect of including both these studies in the meta-analysis.

Outcomes included in our analysis {generally coded to the *International Classification of Diseases, 10th Revision* \[ICD-10; World Health Organization (WHO) 1992\]} had to fall within one of the four major subtypes of circulatory disease determined *a priori*: ischemic heart disease (IHD, ICD-10 I20--I25); heart disease apart from IHD (non-IHD; ICD-10 I26--I52); cerebrovascular disease (CVA; ICD-10 I60--I69); and all other circulatory diseases (ICD-10 I00--I19, I53--I59, I70--I99). This resulted in the exclusion of the [@r46] study, which assessed only heart disease and so cannot be included within any of these four disease end points. For each study, we selected disjoint end-point groups with maximum coverage within these four circulatory disease subtype groups. We used morbidity rather than mortality data from the Mayak worker studies of [@r5], [@r6]) because of the significant loss of follow-up for the mortality study and low diagnostic accuracy for death certificate reporting for this cohort.

The results of the PubMed and ISI Thomson searches were cross-checked by M.P.L. and W.Z. Additional checks were made using ISI Thomson citations of various review articles ([@r25]; [@r28]) and other sources as detailed in [@r25]. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group guidelines for meta-analysis were used ([@r43]) \[see Supplemental Material, [Table S1](#ehp-1204982-s001){ref-type="supplementary-material"} (<http://dx.doi.org/10.1289/ehp.1204982>) for a checklist indicating compliance with MOOSE guidelines\].

A total of 10 studies met our criteria for inclusion. Although the Japanese data ([@r39]; [@r57]) and many of the occupational studies included individuals with cumulative absorbed dose ranges of \> 0.5 Sv, mean cumulative whole-body doses from external sources of radiation in cohorts included in our analysis were generally \< 0.2 Sv \[with the exception of the Mayak worker study, which had a mean dose of about 0.8 Gy ([@r5], [@r6])\], and the occupational cohorts were all exposed at low daily dose rates (generally \< 1 mSv/day, and all \< 10 mSv/day). Details regarding the quality of dosimetry, assessment of disease end points, selection criteria to determine cohort eligibility, circulatory disease risk factors assessed, and statistical analyses used in the 10 studies are provided in Supplemental Material, [Table S2](#ehp-1204982-s001){ref-type="supplementary-material"} (<http://dx.doi.org/10.1289/ehp.1204982>).

*Statistical methods for meta-analysis.* The analytical techniques extend those employed previously (AGIR 2010; [@r25], [@r27], [@r26]) to analyze different data (including studies of medically exposed populations as well as the studies included in this analysis). Pooled excess relative risk (ERR) per sievert were estimated for the four circulatory disease subgroups defined above.

In the absence of significant heterogeneity, we computed the best linear unbiased estimate (inverse-variance weighted) of ERR (*ERR~tot~*) as
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where *ERR~i~* indicates the ERR reported in the *i*th study. This estimate has an SD given by
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These formulae were used to compute aggregate measures of ERR and their associated 95% confidence intervals \[obtained as *ERR*~tot~ ± *N*~0.975~ × *sd*(*ERR*~tot~)\] in [Table 2](#t2){ref-type="table"}. (*N*~0.975~ ≈ 1.96 is the 97.5th percentile point of the standard normal distribution.) One-sided *p*-values were computed from the centiles of the normal distribution. [Equation 2](#e2){ref-type="disp-formula"} provides a consistent estimate of the SD. SDs were estimated for the individual studies based on confidence intervals reported in the published papers.

###### 

Estimated ERRs of circulatory disease in the Japanese atomic-bomb survivors and occupational and environmental exposure studies.

  Data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Reference                                  Mean heart/brain dose (range) (Sv)   No. in cohort (person-years follow-up)   End point (mortality)^a^                         ERR/Sv (95% CI)
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------ ------------------------------------ ---------------------------------------- ------------------------------------------------ -------------------------
  Japanese atomic-bomb survivors                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  Mortality                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Shimizu et al. 2010                        0.1 (0 to 4)b                        86,611 (NA)                              IHD (ICD-9 410--414)                             0.02 (--0.10, 0.15)
  Rheumatic heart disease (ICD-9 393--398)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         0.86 (0.25, 1.72)                                                                                                                                                         
  Heart failure (ICD-9 428)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        0.22 (0.07, 0.39)                                                                                                                                                         
  Other heart disease (ICD-9 390--392, 415--427, 429)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              --0.01 (--0.21, 0.24)                                                                                                                                                     
  CVA total (ICD-9 430--438)c                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      0.12 (0.05, 0.19)c                                                                                                                                                        
  Circulatory disease apart from heart disease and stroke (ICD-9 390--392, 401, 403, 405, 439--459)c                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               0.58 (0.45, 0.72)c                                                                                                                                                        
  Morbidity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Yamada et al. 2004                         0.1 (0 to 4)d                        10,339 (NA)                              Hypertension incidence, 1958--1998 (ICD-9 401)   0.05 (--0.01, 0.10)d
  Hypertensive heart disease incidence, 1958--1998 (ICD-9 402, 404)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                --0.01 (--0.09, 0.09)d                                                                                                                                                    
  IHD incidence, 1958--1998 (ICD-9 410--414)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       0.05 (--0.05, 0.16)d                                                                                                                                                      
  Aortic aneurysm incidence, 1958--1998 (ICD-9 441, 442)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           0.02 (--0.22, 0.41)d                                                                                                                                                      
  CVA incidence, 1958--1998 (ICD-9 430, 431, 433, 434, 436)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        0.07 (--0.08, 0.24)d                                                                                                                                                      
  Occupational studies                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  Mayak workers                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Azizova et al. 2010a, 2010b                0.83 (0 to 5.92)e                    12,210 (205,249)                         IHD morbidity (ICD-9 410--414)                   0.119 (0.051, 0.186)e,f
  12,210 (249,530)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 CVA morbidity (ICD-9 430--432, 434, 436)   0.449 (0.338, 0.559)e,f                                                                                                        
  Chernobyl emergency workers                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Ivanov et al. 2006                         0.109 (0 to \> 0.5)                  61,017 (NA)                              Hypertension (ICD-10 I10--I15) morbidity         0.26 (--0.04, 0.56)
  IHD (ICD-10 I20--I25) morbidity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  0.41 (0.05, 0.78)                                                                                                                                                         
  Other heart disease (ICD-10 I30--I52) morbidity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  --0.26 (--0.81, 0.28)                                                                                                                                                     
  CVA (ICD-10 I60--I69) morbidity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  0.45 (0.11, 0.80)                                                                                                                                                         
  Morbidity from diseases of arteries, arterioles, and capillaries (ICD-10 I70--I79)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               0.47 (--0.15, 1.09)                                                                                                                                                       
  Morbidity from diseases of veins, lymphatic vessels, and lymph nodes (ICD-10 I80--I89)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           --0.26 (--0.70, 0.18)                                                                                                                                                     
  German uranium miner study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Kreuzer et al. 2006                        0.041 (0 to 0.909)e                  59,001 (1,801,626)                       CVA (ICD-10 I60--I69)                            0.09 (--0.6, 0.8)e
  EdF workers                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Laurent et al. 2010                        0.0215 (0 to 0.6)                    22,393 (440,984)                         IHD (ICD-10 I20--I25)                            4.1 (--2.9, 13.7)g
  CVA (ICD-10 I60--I69)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            17.4 (0.2, 43.9)g                                                                                                                                                         
  Eldorado uranium miners and processing (male) workers                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Lane et al. 2010                           0.0522 (\< 0.0234 to \> 0.1215)      16,236 (508,673)                         IHD (ICD-10 I20--I25)                            0.15 (--0.14, 0.58)
  CVA (ICD-10 I60--I69)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            --0.29 (\< --0.29, 0.27)                                                                                                                                                  
  Third analysis of UK National Registry for Radiation Workers                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Muirhead et al. 2009                       0.0249 (\< 0.01 to \> 0.4)           174,541 (3,900,000)                      IHD (ICD-9 410--414)                             0.259 (--0.05, 0.61)
  CVA (ICD-9 430--438)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             0.161 (--0.42, 0.91)                                                                                                                                                      
  IARC 15-country nuclear worker study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Vrijheid et al. 2007                       0.0207 (0.0 to \> 0.5)               275,312 (4,067,861)                      IHD (ICD-10 I20--I25)                            --0.01 (--0.59, 0.69)
  Heart failure (ICD-10 I50)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       --0.03 (\< 0, 4.91)                                                                                                                                                       
  CVA (ICD-10 I60--I69)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            0.88 (--0.67, 3.16)                                                                                                                                                       
  NA, not available. All data are in relation to underlying cause of death, unless otherwise indicated. Adapted from Little et al. (2008, 2010). aCoded to the International Classification of Diseases, 9th Revision (ICD-9; WHO 1977) or to ICD-10 (WHO 1992). bAnalysis based on colon dose. cAnalysis using underlying or contributing cause of death. dAnalysis based on stomach dose, derived from Table 3 of Yamada et al. (2004) with smoking and drinking in the stratification. eRisk estimates in relation to cumulative whole body external gamma dose. fAssuming a lag period of 10 years. g90% CI.                                                                                                                                                                             

Heterogeneity was assessed via the standard χ^2^ statistic and calculated as
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The above estimates correspond to a fixed-effect model, in which *ERR~i~* \~ *N*(μ, σ*~i~*^2^). When heterogeneity is statistically significant (assessed by comparing *Q* with centiles of the chi-square distribution with the appropriate number of degrees of freedom = *N* -- 1) a random-effects model is more appropriate, in which we assume *ERR~i~* \| δ*~i~* \~ *N*(μ *+* δ*~i~*,σ*~i~*^2^) and that δ*~i~ \~ N*(0,Δ^2^). The random-effects model assumes that inference is being made about a hypothetical population of studies of which the observed studies involved are assumed to constitute a "random sample" of potential studies of the same effects. Following [@r11], we computed the 1-step estimate of Δ^2^ by equating the statistic *Q* and its expectation under this model to obtain
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Similarly to the above, we then computed the best linear unbiased estimate (inverse-variance weighted) of ERR, given by
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Similarly to the above, this estimate has an SD given by
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\[6\]

We estimated 1-sided *p*-values (assuming only detrimental effects) in the standard way from the mean, μ, and SD, σ, derived from the meta-analysis for each circulatory disease end point, as *p*\[*N*(0,1) \< --μ*/*σ\]. Statistical significance was defined by *p \<* 0.05. The Egger test of publication/selection bias ([@r13]; [@r41]) and the [@r12] "trim-and-fill" method of correction for publication/selection bias were employed, as shown in Supplemental Material, [Table S3](#ehp-1204982-s001){ref-type="supplementary-material"} (<http://dx.doi.org/10.1289/ehp.1204982>). All statistical models were fitted using Stata/SE 11.2 for Windows (32 bit) (StataCorp, College Station, TX).

*Estimates of population risks.* We used pooled ERR from the meta-analysis to derive population-based excess absolute risk (EAR) estimates according to underlying cause-specific mortality rates for each population. Specifically, we used estimates for the year 2003 in England and Wales ([@r32]), 2009 for Japan ([@r40]), and the latest available WHO (2010) data for the following countries: China, for 2000; France, 2007; Germany, 2006; Russia, 2006; Spain, 2005; Ukraine, 2008; and the United States, 2005. We assumed a 5-year minimum latency period, after which the ERR was assumed to apply for the remainder of life. For all of the countries listed above, we estimated the risk of exposure-induced death (REID) per sievert, years of life lost per sievert, and years of life lost per radiation-induced circulatory disease death, by applying methods previously used to derive comparable estimates for radiation-induced cancer \[United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR) 2008\]. In addition, we obtained population risk estimates for radiation-induced solid cancers (ICD-10 C00--C80) and leukemias excluding chronic lymphocytic leukemia (ICD-10 C91--C95, excluding C91.1) for China, Japan, the United Kingdom, and the United States for comparison with population risk estimates for circulatory diseases (UNSCEAR 2008).

Results
=======

*Meta-analysis*. A funnel plot shows little evidence of publication or selection bias in the meta-analysis---at least once the very large (but imprecise) ERRs in one study ([@r21]) are removed ([Figure 1](#f1){ref-type="fig"}). More formally, an Egger test for bias ([@r13]) revealed no significant evidence for publication or selection bias in any circulatory disease end point: Egger test *p*-values ranged from 0.322 for IHD to 0.692 for CVA, and little difference was made to risk coefficients if trim-and-fill publication/selection-bias correction methods were used ([@r12]) \[see Supplemental Material, [Table S3](#ehp-1204982-s001){ref-type="supplementary-material"} (<http://dx.doi.org/10.1289/ehp.1204982>)\].

![Funnel plot of ERR/Sv versus SE of ERR. Each circulatory disease end point comprising each of the four main circulatory disease subtypes (IHD, non-IHD, CVA, all circulatory disease apart from heart disease and stroke) for each study considered in the meta-analysis is plotted separately (*A*). The red line shows the aggregate random-effects ERR estimate. (*B*) Data excluding the study of [@r21].](ehp.1204982.g001){#f1}

[Table 1](#t1){ref-type="table"} demonstrates that most ERR estimates (22 of 29) are positive, and with the exception of the study of [@r21] are generally of modest size, with absolute values of \< 1/Sv. The results of the meta-analysis ([Table 2](#t2){ref-type="table"}) using a random-effects model show a statistically significant ERR per sievert for IHD \[ERR = 0.10/Sv, 95% confidence interval (CI): 0.04, 0.15, 1-sided *p \<* 0.001\], CVA (ERR = 0.21/Sv, 95% CI: 0.02, 0.39, 1-sided *p* = 0.014), and circulatory disease apart from heart disease and stroke (ERR = 0.19/Sv, 95% CI: --0.00, 0.38, 1-sided *p* = 0.026; --0.00 indicates that the number is between --0.005 and 0). The ERR for non-IHD is significant at least for the fixed-effect model (ERR = 0.12/Sv, 95% CI: --0.01, 0.25, 1-sided *p* = 0.031), but not for the random-effects model (ERR = 0.08/Sv, 95% CI: --0.12, 0.28, 1-sided *p* = 0.222) ([Table 2](#t2){ref-type="table"}). The heterogeneity in ERR between the various studies and end points for IHD and non-IHD is not statistically significant (*p* \> 0.1), although it is significant for the other end points (*p* ≤ 0.001; [Table 2](#t2){ref-type="table"}).

###### 

ERR coefficients for circulatory diseases as a result of exposure to low-level radiation ≥ 5 years earlier, by disease.

  Disease                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 References                                                                                                                                                                                   Fixed-effect estimate of ERR/Sv (95% CI)   Random-effect estimate of ERR/Sv (95% CI)   1-sided significance, *p*-value (fixed effect/random effect)   Heterogeneity χ^2^ (df)/*p*-value
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------ ------------------------------------------- -------------------------------------------------------------- -----------------------------------
  IHD (ICD-10 I20--I25)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Azizova et al. 2010aa, Ivanov et al. 2006, Lane et al. 2010, Laurent et al. 2010, Muirhead et al. 2009, Shimizu et al. 2010, Vrijheid et al. 2007, Yamada et al. 2004                        0.10 (0.05, 0.15)                          0.10 (0.04, 0.15)                           \< 0.001/\< 0.001                                              7.20 (7)/0.408
  Non-IHD (ICD-10 I26--I52)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Ivanov et al. 2006, Shimizu et al. 2010b, Vrijheid et al. 2007c                                                                                                                              0.12 (--0.01, 0.25)                        0.08 (--0.12, 0.28)                         0.031/0.222                                                    4.65 (3)/0.199
  CVA (ICD-10 I60--I69)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Azizova et al. 2010bd, Ivanov et al. 2006, Kreuzer et al. 2006, Lane et al. 2010, Laurent et al. 2010, Muirhead et al. 2009, Shimizu et al. 2010, Vrijheid et al. 2007, Yamada et al. 2004   0.20 (0.14, 0.25)                          0.21 (0.02, 0.39)                           \< 0.001/0.014                                                 34.28 (8)/\< 0.001
  Circulatory disease apart from heart disease and CVA (ICD-10 I00--I19, I53--I59, I70--I99)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Ivanov et al. 2006e, Shimizu et al. 2010f, Yamada et al. 2004g                                                                                                                               0.10 (0.05, 0.14)                          0.19 (--0.00, 0.38)                         \< 0.001/0.026                                                 66.83 (7)/\< 0.001
  Values are from Table 1, unless otherwise indicated. aAnalysis based on morbidity from IHD, with a 10-year lag. bAnalysis based on mortality from heart failure and other heart disease. cAnalysis based on mortality from heart failure. dAnalysis based on morbidity from CVA, with a 10-year lag. eAnalysis based on morbidity from hypertension, disease of arteries, arterioles and capillaries, veins, lymphatic vessels, and lymph nodes. fAnalysis based on mortality from rheumatic heart disease and circulatory disease apart from heart disease and CVA. gAnalysis based on morbidity from hypertension, hypertensive heart disease, and aortic aneurysm.                                                                                                                                                                                                                                                                                                                                                      

In general, ERR estimates were not particularly sensitive to the removal of individual studies \[see Supplemental Material, [Table S4](#ehp-1204982-s001){ref-type="supplementary-material"}, (<http://dx.doi.org/10.1289/ehp.1204982>)\], though effects were greater for the end points addressed by only a few studies, in particular non-IHD (three studies) and all circulatory disease apart from heart disease and CVA (three studies). Exclusion of the Mayak workforce studies ([@r5], [@r6]) had the greatest effect, resulting in a random-effect ERR for IHD of 0.07 (95% CI: --0.01, 0.15) compared with 0.10 (95% CI: 0.04, 0.15) and 0.12 (95% CI: 0.02, 0.23) for CVA compared with 0.21 (95% CI: 0.02, 0.39). The addition of the [@r35] or the [@r29] data to the IHD category (the only circulatory disease group to which they can contribute) makes very little difference: The fixed-effects ERR changes from 0.10 (95% CI: 0.05, 0.15) ([Table 2](#t2){ref-type="table"}) to 0.10 (95% CI: 0.06, 0.15) or 0.10 (95% CI: 0.05, 0.15), respectively, and the random-effects ERR changes from 0.10 (95% CI: 0.04, 0.15) ([Table 2](#t2){ref-type="table"}) to 0.13 (95% CI: 0.04, 0.23) or 0.09 (95% CI: 0.03, 0.16), respectively.

*Population risks*. Population-based EAR estimates for REID for all circulatory disease range from 2.50%/Sv (CI: 0.77, 4.22) for France to 8.51%/Sv (95% CI: 4.00, 13.02) for Russia, reflecting the underlying risk of circulatory disease mortality ([Table 3](#t3){ref-type="table"}). Estimated circulatory disease mortality risks are generally dominated (in Germany, Russia, Ukraine, the United Kingdom, and the United States) by IHD and CVA ([Tables 3](#t3){ref-type="table"} and [4](#t4){ref-type="table"}). The random-effects model, based on aggregate ERR data from individual studies without age-at-exposure information, predicts that population circulatory disease EAR (i.e., REID) in the United Kingdom varies minimally with age at exposure ([Table 5](#t5){ref-type="table"}). However, in this instance more weight should be attached to models fitted to the current Japanese atomic-bomb survivor mortality data of [@r39] \[see Supplemental Material, [Tables S5 and S6](#ehp-1204982-s001){ref-type="supplementary-material"} (<http://dx.doi.org/10.1289/ehp.1204982>)\], which provides information on variation of risk by age at exposure: risks reduce from 20.73%/Sv at ≤ 9 years of age to 2.05%/Sv at ≥ 70 years of age ([Table 5](#t5){ref-type="table"})\]. In this review, we found indications of the same direction of trend with age at exposure also in the French nuclear workers ([@r21]), although there are no such trends (but apparently little power to assess them) in the IARC study ([@r50]) (results not shown).

###### 

Estimated EAR of REID for various subtypes of circulatory disease, by country.

  Country (year underlying mortality rates were determined)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Baseline proportion of deaths due to circulatory disease (%)   REID × 10^--2^/Sv (95% CI)                                                                                                                
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------- ---------------------------- --------------------- ------------------- --------------------- -------------------- ------- ------- ------- -------
  China (2000)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           42.1                                                           0.92 (0.41, 1.42)            0.11 (--0.16, 0.37)   4.31 (0.48, 8.14)   1.43 (--0.01, 2.86)   6.76 (2.63, 10.89)   3.95c   3.89d   0.27e   0.42f
  France (2007)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          20.8                                                           0.50 (0.22, 0.78)            0.54 (--0.85, 1.94)   0.92 (0.10, 1.74)   0.53 (--0.00, 1.05)   2.50 (0.77, 4.22)    ---     ---             
  Germany (2006)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         48.7                                                           1.71 (0.76, 2.65)            0.97 (--1.52, 3.46)   1.69 (0.19, 3.19)   1.38 (--0.01, 2.76)   5.75 (2.39, 9.10)    ---     ---             
  Japan (2009)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           31.1                                                           0.57 (0.25, 0.88)            0.80 (--1.25, 2.85)   2.19 (0.24, 4.14)   0.45 (--0.00, 0.91)   4.01 (1.13, 6.89)    4.65c   4.90d   0.32e   0.43f
  Russia (2006)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          64.4                                                           2.82 (1.26, 4.39)            0.31 (--0.49, 1.11)   4.59 (0.51, 8.66)   0.79 (--0.00, 1.57)   8.51 (4.00, 13.02)   ---     ---             
  Spain (2005)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           35.8                                                           0.91 (0.41, 1.42)            0.82 (--1.28, 2.52)   1.91 (0.21, 3.60)   0.81 (--0.00, 1.63)   4.45 (1.73, 7.17)                            
  Ukraine (2008)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         69.2                                                           4.14 (1.85, 6.43)            0.20 (--0.31, 0.70)   2.85 (0.31, 5.39)   0.93 (--0.00, 1.85)   8.11 (4.53, 11.69)                           
  United Kingdom (2003)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  39.9                                                           1.70 (0.76, 2.64)            0.37 (--0.58, 1.32)   2.24 (0.25, 4.22)   0.76 (--0.00, 1.53)   5.07 (2.55, 7.58)    5.15c   4.40d   0.38e   0.43f
  United States (2005)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   39.3                                                           1.82 (0.81, 2.82)            0.57 (--0.89, 2.03)   1.29 (0.14, 2.44)   0.80 (--0.00, 1.61)   4.48 (2.22, 6.74)    4.74c   4.41d   0.47e   0.42f
  CLL, chronic lymphocytic leukemia. All calculations assume a single acutely delivered test dose of 0.01 Sv, and are calculated assuming a random-effects model. Cancer data are from UNSCEAR (2008). aRelative risk coefficients for IHD, non-IHD, CVA, and all circulatory disease apart from heart disease and CVA are from Table 2. bObtained by summing the risks from component disease categories (IHD, non-IHD, CVA, and other circulatory). cRelative risk model with linear-quadratic dose response, adjusted for sex, age, and years since exposure. dAdditive risk model with linear-quadratic dose response, adjusted for age and years since exposure. eRelative risk model with linear-quadratic dose response, adjusted for age. fAdditive risk model with linear-quadratic dose response, adjusted for sex and years since exposure.                                                                                                                                                                                                            

###### 

Estimated population mortality risks for subtypes of circulatory disease and cancer in the United Kingdom.

  Disease                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                REID × 10--2/Sv (95% CI)   Years of life lost/Sv (95% CI)   Years of life lost/ radiation-induced death (95% CI)
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------- -------------------------------- ------------------------------------------------------
  IHD (ICD-10 I20--I25)a                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 1.70 (0.76, 2.64)          0.146 (0.065, 0.227)             8.61 (8.61, 8.61)
  Non-IHD (ICD-10 I26--I52)a                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             0.37 (--0.58, 1.32)        0.027 (--0.043, 0.097)           7.36 (7.36, 7.36)
  CVA (ICD-10 I60--I69)a                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 2.24 (0.25, 4.22)          0.162 (0.018, 0.307)             7.26 (7.26, 7.26)
  Other circulatory disease (ICD-10 I00--I19, I53--I59, I70--I99)a                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       0.76 (--0.00, 1.53)        0.065 (--0.000, 0.130)           8.50 (8.50, 8.50)
  All circulatory disease (ICD-10 I00--I99)b                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             5.07 (2.55, 7.58)          0.400 (0.209, 0.591)             7.90 (7.90, 7.90)
  Solid cancerc                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          5.15                       0.711                            13.8
  Solid cancerd                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          4.40                       0.632                            14.4
  Leukemiae                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              0.38                       0.075                            19.8
  Leukemiaf                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              0.43                       0.135                            31.6
  All calculations assume a single acutely delivered test dose of 0.01 Sv, and are calculated assuming a random-effects model. aRelative risk coefficients for IHD, non-IHD, CVA, and all circulatory disease apart from heart disease and CVA are from Table 2. bObtained by summing the risks from component disease categories (IHD, non-IHD, CVA, and other circulatory). cRelative risk model with linear-quadratic dose response, adjusted for sex, age, and years since exposure (taken from UNSCEAR 2008). dAdditive risk model with linear-quadratic dose response, adjusted for age and years since exposure (taken from UNSCEAR 2008). eRelative risk model with linear-quadratic dose response, adjusted for age (taken from UNSCEAR 2008). fAdditive risk model with linear-quadratic dose response, adjusted for sex and years since exposure (taken from UNSCEAR 2008).                                                               

###### 

Variation of population mortality risks of circulatory disease and cancer with age at exposure in the United Kingdom.

  Age at exposure, years                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Circulatory disease   Cancer                                                                                                                        
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ --------------------- -------- ------------------- ---------------------- ---------- --------- ---------- ---------- --------- --------- ---------- ----------
  0--9                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             20.73                 1.836    5.25 (2.67, 7.83)   0.459 (0.242, 0.676)   11.07b,c   8.36c,d   1.798b,c   1.412c,d   0.74c,e   0.70c,f   0.270c,e   0.335c,f
  10--19                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           14.18                 1.260    5.26 (2.68, 7.84)   0.459 (0.242, 0.676)   9.19b,c    7.39c,d   1.371b,c   1.199c,d   0.52c,e   0.65c,f   0.118c,e   0.269c,f
  20--29                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           10.09                 0.898    5.27 (2.69, 7.86)   0.458 (0.242, 0.674)   7.45b,c    6.34c,d   1.042b,c   0.966c,d   0.46c,e   0.59c,f   0.080c,e   0.208c,f
  30--39                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           7.48                  0.661    5.29 (2.69, 7.89)   0.453 (0.240, 0.667)   5.77b,c    5.20c,d   0.742b,c   0.722c,d   0.43c,e   0.53c,f   0.065c,e   0.153c,f
  40--49                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           5.75                  0.494    5.30 (2.70, 7.90)   0.439 (0.232, 0.646)   4.15b,c    4.01c,d   0.475b,c   0.486c,d   0.40c,e   0.46c,f   0.053c,e   0.105c,f
  50--59                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           4.53                  0.364    5.30 (2.68, 7.91)   0.410 (0.215, 0.606)   2.68b,c    2.83c,d   0.259b,c   0.284c,d   0.37c,e   0.38c,f   0.042c,e   0.065c,f
  60--69                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           3.57                  0.249    5.19 (2.59, 7.80)   0.355 (0.181, 0.528)   1.48b,c    1.75c,d   0.113b,c   0.136c,d   0.31c,e   0.29c,f   0.029c,e   0.035c,f
  ≥ 70                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             2.05                  0.107    3.90 (1.83, 5.96)   0.200 (0.095, 0.305)   0.45b,c    0.66c,d   0.025b,c   0.036c,d   0.17c,e   0.16c,f   0.011c,e   0.011c,f
  All age                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          8.53                  0.732    5.07 (2.55, 7.58)   0.400 (0.209, 0.591)   5.15b      4.40d     0.711b     0.632d     0.38e     0.43f     0.075e     0.135f
  All calculations assume a single acutely delivered test dose of 0.01 Sv (unless otherwise indicated), and are calculated assuming a random-effects model. Cancer data are from UNSCEAR (2008). The Life Span Study (LSS) predictions given in columns 2, 3 are based on the optimal model (model 5) fitted to the data of Shimizu et al. (2010) shown in Supplemental Material, Table S6 (http://dx.doi.org/10.1289/ehp.1204982). aObtained by summing the risks from component disease categories (IHD, non-IHD, CVA, and other circulatory). bRelative risk model with linear-quadratic dose response, adjusted for sex, age, and years since exposure. cSingle acutely delivered test dose of 0.1 Sv. dAdditive risk model with linear-quadratic dose response, adjusted for age and years since exposure. eRelative risk model with linear-quadratic dose response, adjusted for age. fAdditive risk model with linear-quadratic dose response, adjusted for sex and years since exposure.                                                                                                                                                       

In aggregate, EAR coefficients are similar to those for cancer mortality, and the indications are that, as for cancer, there is a pronounced reduction of risk with increasing age at exposure ([Table 5](#t5){ref-type="table"}); for example, UNSCEAR (2008) estimated that the total cancer REID is in the range 4.16--5.58% for China, Japan, the United Kingdom, and the United States ([Table 3](#t3){ref-type="table"}). In different terms, the risks for a UK population are 0.146 (95% CI: 0.065, 0.227) years of life lost per sievert and 8.61 years of life lost per radiation-induced death, and 0.162 years of life lost per sievert (95% CI: 0.018, 0.307) and 7.26 years of life lost per radiation-induced death, for IHD and CVA, respectively ([Table 4](#t4){ref-type="table"}). These years of life lost per radiation-induced death figures are substantially lower than the corresponding ones for solid cancers (13.8--14.4 years) and leukemia (19.8--31.6 years; [Table 4](#t4){ref-type="table"}), reflecting the fact that circulatory disease mortality tends to occur later in life.

Discussion
==========

We estimated statistically significant ERRs for four subtypes of circulatory disease in persons exposed to radiation. There was significant heterogeneity among individual study estimates for CVA and other circulatory diseases, but not for IHD and non-IHD. These results confirm and extend a previous analysis that also found statistically significant ERRs for IHD and CVA (AGIR 2010).

Most of the studies considered in the present review involved low-to-moderate mean cumulative radiation doses (≤ 0.2 Gy), with participants in the occupational studies exposed at near-background dose rates. Nevertheless, the small numbers of participants exposed at high cumulative doses (≥ 0.5 Gy) drive the observed trends in most cohorts with these higher dose groups ([Table 1](#t1){ref-type="table"}).

Population-based EAR estimates for circulatory disease mortality were dominated by estimated risks for IHD and CVA, which is unsurprising, given that deaths from these two end points account for the largest number of deaths from circulatory disease and that the excess risk is a simple multiple of the underlying circulatory disease risk.

A critical question in these calculations is whether the risk coefficients derived here are applicable to the lower cumulative doses (\< 100 mSv) or low dose rates (\< 5 mSv/hr) of principal relevance to radiological protection. We fitted a linear ERR model to the data in the meta-analysis, so we implicitly assumed a linear association of risk at low doses and dose rates. There is little evidence for nonlinearity in the dose--response curve for circulatory disease in Japanese atomic-bomb survivors ([@r39]; [@r57]) or in the Mayak workers ([@r5], [@r6]), so this assumption seems reasonable in the current analysis. At least for IHD and non-IHD, additional support for a linear relationship between risk and low doses or low dose rates can be derived from the consistency of ERR per sievert between Japanese atomic-bomb survivors with moderate radiation doses at high dose rates ([@r39]; [@r57]) and occupational cohorts with protracted exposures. Currently, an etiologic mechanism for associations between low-level radiation and circulatory disease risk is unclear, so there are no sound biological grounds on which to base selection of a model for extrapolating the risks to low doses or low dose rates (AGIR 2010). However, a candidate mechanism, based on monocyte cell killing in the intima, suggests that circulatory disease risks would be approximately proportional to dose at low dose rates ([@r24]), but because of saturation of repair systems, effects would be greater for exposures to higher doses and dose rates (UNSCEAR 1993). Although this mechanism is consistent with the occupational data, it is speculative and not yet experimentally confirmed. Epidemiological data suggest that circulatory disease risk is significantly elevated only for acute or cumulative doses of about 0.5 Gy and above; nonetheless, the dose rate independence of risk remains (AGIR 2010).

All studies included in the meta-analysis were either of the Japanese atomic-bomb survivors or of occupationally exposed groups. All occupational groups were to some extent selected, from populations that were sufficiently fit to be employed as radiation workers. The degree of selection (as a result of mortality in the period from the bombings in August 1945 to the assembly of the cohort in October 1950) in the Japanese atomic-bomb survivor cohort has long been controversial ([@r23]; [@r42]). There is evidence of selection in at least the earlier years of follow-up for some noncancer end points ([@r33]; [@r34]). As risks in a general unselected population are likely to be higher than in a selected one, it is possible that the risks given here underestimate those that are applicable to a general population; they are more likely to be correct for occupationally exposed groups subject to a similar degree of healthy-worker selection as those considered here.

We estimated ERR, the metric used in most published data (AGIR 2010). Accordingly, for the population risk estimates, we assumed a relative risk model for projecting risk to the end of life, starting 5 years after exposure. ERR does not substantially vary by sex or time since exposure in Japanese atomic-bomb survivors ([@r22]; [@r34]; [@r39]), although there is variation by age at exposure \[see Supplemental Material, [Tables S5, S6](#ehp-1204982-s001){ref-type="supplementary-material"} (<http://dx.doi.org/10.1289/ehp.1204982>)\], and increasing time-since-exposure trends have been observed in other groups ([@r50]). Implicitly, we also assumed that ERR is invariant across populations. This assumption may be reasonable for IHD and non-IHD ERRs, which did not show statistically significant heterogeneity across exposed populations (Japanese atomic-bomb survivors and largely European/American occupational data), but this assumption may not be appropriate for the other circulatory disease subgroups, where heterogeneity was significant.

Candidate biological mechanisms for the effects of radiation on circulatory disease have been recently reviewed (AGIR 2010; [@r25]; [@r37]). At high radiotherapeutic doses (\> 5 Gy), the cell-killing effect on capillaries and endothelial cells plausibly explains effects on the heart and other parts of the circulatory system ([@r37]). At lower doses (i.e., 0.5--5 Gy), human data and *in vivo* and *in vitro* experiments have demonstrated that many inflammatory markers are up-regulated long after exposure to radiation, although for exposures less than about 0.5 Gy the balance shifts toward anti-inflammatory effects ([@r25]; [@r30]), implying that the initiating mechanisms for adverse effects in this dose range would not directly result from inflammation. A recent analysis of renal failure mortality in the atomic-bomb survivors suggests that radiation-induced renal dysfunction may be a factor in causing increased circulatory disease ([@r1]).

The generally uniform whole-body, low linear energy transfer radiation in the cohorts we analysed is uninformative as to specific target tissues. What the target tissues are for circulatory system effects at moderate and low doses (\< 0.5 Gy) remains uncertain. Dose-related variations in T-cell and B-cell populations in Japanese atomic-bomb survivors suggest that the immune system may be adversely affected ([@r19]). Together with the known involvement of the immune system in cardiovascular disease ([@r9]; [@r36]; [@r51]), these results suggest that whole-body or bone-marrow dose might be the most relevant to radiation effects. A mechanism based on monocyte cell killing in the arterial intima suggests that the target for atherosclerosis is the arterial intima ([@r24]); however, as noted above, this mechanism remains speculative.

In their reviews, [@r25], [@r26]) have documented abundant radiobiological reasons for considering studies of moderate and low doses separately from studies of high (i.e., radiotherapeutic) doses because mechanisms of effect are likely to differ. That said, the risks observed in radiotherapeutic studies \[see Supplemental Material, [Table S7](#ehp-1204982-s001){ref-type="supplementary-material"} (<http://dx.doi.org/10.1289/ehp.1204982>)\] are not inconsistent with those in the lower-dose studies that are the focus of the present review and suggest common mechanisms over this dose range. However, given the modest level of excess risk at these lower doses, and the many lifestyle factors that can affect the risk of circulatory disease, attributing causation to the observed associations requires caution. Interpreting the results of studies in which there is no, or at best limited, lifestyle information, that is to say in studies apart from the Japanese atomic-bomb survivors ([@r39]; [@r57]) and the Mayak nuclear workers ([@r5], [@r6]), would be particularly speculative.

The substantial and statistically significant heterogeneity in the estimated relative risks of circulatory disease apart from heart disease among the studies considered is not surprising given variation in the distributions of different risk factors across populations, but it limits interpretation of the observed associations for these end points. Epidemiological research has identified specific risk factors for circulatory disease, including male sex, family history of heart disease, cigarette smoking, diabetes, high blood pressure, obesity, increased low-density lipoprotein cholesterol, and decreased high-density lipoprotein cholesterol plasma levels ([@r7]; [@r55]). Lifestyle factors (in particular, shift work in occupational groups) ([@r47]) and infections ([@r9]; [@r36]; [@r51]) are also potential risk factors for circulatory disease. We could not correct for any of these variables in our meta-analysis. Statistical methods (i.e., random-effects models) are available to accommodate heterogeneity ([@r11]), but these methods may not adequately account for the variation induced by confounding or effect modification. The interactions of these risk factors with possible radiation effects are unknown, but confounding or effect modification cannot be ruled out in studies in which no adjustment was made; in the two cohorts where it was possible to make adjustment for such risk factors little difference was made to radiation risk ([@r5], [@r6]; [@r39]).

A potential problem in meta-analyses is publication bias, which selects against studies that do not produce significant findings, potentially biasing pooled estimates upwards, or selection bias on the part of those selecting the cohorts from the database searches, which could be either positive or negative. We believe that publication bias is unlikely because radiation-induced cardiovascular disease has been an issue in the Japanese atomic-bomb survivor data for at least 15 years ([@r34]; [@r38]; [@r56]); in consequence, such negative findings are likely to be of sufficient interest to be published, and therefore this should not greatly affect the findings of our meta-analysis, concentrating as it does on results published since 1990. There is little internal evidence of either publication or selection bias \[[Figure 1](#f1){ref-type="fig"}; see also Supplemental Material, [Table S3](#ehp-1204982-s001){ref-type="supplementary-material"} (<http://dx.doi.org/10.1289/ehp.1204982>)\], although at least for the end points of non-IHD and all other circulatory disease, the Egger test has little power. The fact that the two persons (M.P.L., W.Z.) evaluating the database search agreed on the included studies also suggests that selection bias is minimal.

We chose to limit our results to studies published as full papers and referenced in PubMed or ISI Thomson. We judged that the most important and high quality studies are likely to be published as full papers. All of the studies selected were cohort studies (although this was not a criterion for being chosen), and all had reasonable quality dosimetry \[see Supplemental Material, [Table S2](#ehp-1204982-s001){ref-type="supplementary-material"} (<http://dx.doi.org/10.1289/ehp.1204982>)\]. Only two of the studies, those of the Japanese atomic-bomb survivors ([@r39]) and of Mayak workers ([@r5], [@r6]), had information on lifestyle factors, in particular cigarette smoking, drinking, and other variables associated with circulatory disease. The lack of evidence of strong positive associations between various nonmalignant smoking-related respiratory diseases and dose in various worker studies ([@r21]; [@r31]; [@r50]) suggests that cigarette smoking is unlikely to have been an important positive confounder of the association with circulatory disease in these groups, and that bias will therefore be if anything towards the null. Information on socioeconomic status (industrial vs. nonindustrial, educational level) in various worker studies ([@r21]; [@r29]; [@r31]; [@r50]) provides only partial control for confounding by lifestyle/environmental risk factors.

Although we eliminated studies with a large degree of overlap, some degree of overlap remained among studies included in the meta-analysis, particularly for the morbidity and mortality data for the Japanese atomic-bomb survivors ([@r39]; [@r57]). However, the largest component of circulatory disease morbidity, hypertension (about half the total number of cases), has a much lower ERR, 0.05/Sv ([@r57]), than either CVA, 0.12/Sv, or heart disease, 0.18/Sv, mortality ([@r39]), suggesting that the overlap may not be large. There is also likely to be statistical dependence between the risks of some end points within the atomic-bomb survivor morbidity study ([@r57]), although in the most likely overlapping categories (hypertension, hypertensive heart disease, CVA), the numbers involved are relatively modest. The effect of removing the morbidity study ([@r57]) from the analysis \[see Supplemental Material, [Table S4](#ehp-1204982-s001){ref-type="supplementary-material"} (<http://dx.doi.org/10.1289/ehp.1204982>)\] is generally to slightly increase risks; there is a more substantial elevation for circulatory disease apart from heart disease and CVA, but this contributes relatively modestly (6--25%) to overall circulatory disease mortality ([Table 3](#t3){ref-type="table"}). There is overlap between the UK worker study ([@r31]) and the 15-country worker study ([@r50]), but this is probably not substantial because the former has 9 more years of follow-up (1993--2001) and the latter includes data from 14 countries in addition to the United Kingdom.

Some of the heterogeneity that we observed in relation to circulatory disease apart from heart disease is driven by morbidity versus mortality differences, reinforcing previous findings ([@r26]). Although one can argue that relative risks should not be different for mortality and morbidity (although absolute risks very well could be), the varying definitions and ascertainment of morbidity end points mean that different degrees of severity of circulatory disease are being encompassed. The relative risks of mortality data should be more similar (than mortality vs. morbidty) ([@r26]), although the uncertainty from misclassification remains and varies over time. Both outcome and exposure misclassification would be expected to bias results toward the null in most cases, unless the bias was differential (e.g., outcome misclassification associated with exposure) ([@r8]). We used morbidity and mortality data in the Japanese atomic-bomb survivors, which contribute to some extent independently (as discussed above) and are of similar quality ([@r39]; [@r57]). However, we used morbidity rather than mortality data in the Mayak worker studies ([@r5], [@r6]) because of the significant problems with the loss of follow-up in the mortality data (which occurred as soon as workers moved out of the closed cities in the ex-USSR) and the much lower diagnostic accuracy in this cohort of death certificate reporting.

In the Japanese atomic-bomb survivors, respiratory and digestive diseases were also elevated ([@r33]; [@r34]), implying a lack of specificity of risk in this cohort. However, there is no evidence of excess risk for any nonmalignant diseases apart from circulatory disease in the other cohorts considered here ([@r21]; [@r31]; [@r50]).

Conclusions
===========

Our meta-analysis supports an association between low doses and low dose rates of ionizing radiation and an excess risk of IHD. For non-IHD, the association is statistically significant when using (as is justifiable, given the homogeneity of risk) a fixed-effect model. The association is less certain for other circulatory diseases given the heterogeneity in these end points among the studies. The evidence presented in this review indicates a need to conduct more detailed epidemiological studies that are capable of addressing potential confounding and misclassifying factors and possible selection bias that could influence these results as well as a particular need for a better understanding of biological mechanisms that might be responsible for the association. The estimates of population-based excess mortality risks for circulatory disease are similar to those for radiation-induced cancer, as also noted previously in relation to noncancer disease ([@r34]). If associations between low-level exposure to radiation and circulatory diseases reflect an underlying causal relationship that is linear at low doses, then the overall excess risk of mortality after exposure to low doses or low dose rates of radiation may be about twice that currently assumed based on estimated risks of mortality due to radiation-induced cancers alone.
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